title: Low-dose low-frequency imiglucerase as a starting regimen of enzyme replacement therapy for patients with type I Gaucher disease.
abstract: The issue of the interplay of optimal dosage and frequency regimens for enzyme replacement therapy in type I Gaucher disease has been a source of controversy during the 7 years since the introduction of the placenta-derived enzymatic preparation in 1991. We present the results of treatment with the human recombinant form of the enzyme in 28 type I Gaucher patients, who have been treated for 6 to 24 months. As long as cost is an important factor in the management of patients with Gaucher disease, low-dose low-frequency imiglucerase promises satisfactory clinical improvement without compromising quality of life.
authors.affiliation: Gaucher Clinic, Shaare-Zedek Medical Center, Jerusalem, Israel.
authors.forename: D
authors.initials: D
authors.lastname: Elstein
authors.forename: A
authors.initials: A
authors.lastname: Abrahamov
authors.forename: I
authors.initials: I
authors.lastname: Hadas-Halpern
authors.forename: A
authors.initials: A
authors.lastname: Meyer
authors.forename: A
authors.initials: A
authors.lastname: Zimran
mesh_terms: D000293:Adolescent; D000328:Adult; D001792:Blood Platelets; D004334:Drug Administration Schedule; D005260:Female; D005776:Gaucher Disease / Q000175:diagnosis / Q000188:drug therapy* / Q000473:pathology; D005962:Glucosylceramidase / Q000008:administration & dosage*; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D008099:Liver / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins / Q000008:administration & dosage; D013154:Spleen / Q000473:pathology
chemical_list: D006454:Hemoglobins; D011994:Recombinant Proteins; D005962:Glucosylceramidase; C090568:imiglucerase